Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

271.36
+4.671.75%
Post-market: 272.000.6400+0.24%17:12 EDT
Volume:5.48M
Turnover:1.49B
Market Cap:479.60B
PE:76.66
High:274.94
Open:268.40
Low:266.89
Close:266.69
52wk High:274.94
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.05
T/O Rate:0.31%
Dividend:6.83
Dividend Rate:2.52%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-80.81
PE(LYR):114.98

Loading ...

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
Oct 06

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
Oct 06

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
Oct 06

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS
·
Oct 06

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS
·
Oct 06

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Oct 06

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
Oct 03

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
Oct 03